-
Tytuł:
-
Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
-
Autorzy:
-
Sato Y; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Nakano K; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; .
Fukuda N; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Wang X; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Urasaki T; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Ohmoto A; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Yunokawa M; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Ono M; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Tomomatsu J; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Hayakawa K; Department of Orthopedic Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Funauchi Y; Department of Orthopedic Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Tanizawa T; Department of Orthopedic Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Ae K; Department of Orthopedic Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Matsumoto S; Department of Orthopedic Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Takahashi S; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
-
Źródło:
-
Anticancer research [Anticancer Res] 2021 Jan; Vol. 41 (1), pp. 527-532.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Attiki, Greece : International Institute of Anticancer Research
Original Publication: Athens, Greece : Potamitis Press
-
MeSH Terms:
-
Leukocyte Count*
Lymphocytes*
Neutrophils*
Antineoplastic Agents/*therapeutic use
Furans/*therapeutic use
Ketones/*therapeutic use
Sarcoma/*blood
Sarcoma/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biomarkers ; Female ; Furans/administration & dosage ; Furans/adverse effects ; Humans ; Kaplan-Meier Estimate ; Ketones/administration & dosage ; Ketones/adverse effects ; Male ; Middle Aged ; Prognosis ; Retreatment ; Retrospective Studies ; Sarcoma/diagnosis ; Sarcoma/mortality ; Treatment Outcome
-
Contributed Indexing:
-
Keywords: NLR; Neutrophil-to-lymphocyte ratio; STS; eribulin; soft-tissue sarcoma
-
Substance Nomenclature:
-
0 (Antineoplastic Agents)
0 (Biomarkers)
0 (Furans)
0 (Ketones)
LR24G6354G (eribulin)
-
Entry Date(s):
-
Date Created: 20210109 Date Completed: 20210125 Latest Revision: 20210125
-
Update Code:
-
20240105
-
DOI:
-
10.21873/anticanres.14804
-
PMID:
-
33419852
-
Background: Eribulin is widely used for the treatment of breast cancer and soft-tissue sarcoma (STS). Previous studies identified the pre-treatment absolute lymphocyte count, baseline neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein concentration as potential prognostic markers in patients with breast cancer treated with eribulin. However, prognostic factors for eribulin treatment in patients with STS have not been identified.
Patients and Methods: This was a retrospective analysis of data collected prospectively from 53 patients who were treated with eribulin for recurrent or metastatic STS between March 2016 and August 2019. Univariate and multivariate analyses were performed to determine the predictive factors of durable clinical benefit, progression-free survival, and overall survival.
Results: L-Sarcoma histology [hazard ratio (HR)=28.20, 95% confidence intervaI (CI)=1.67-476.00; p=0.021] and pre-treatment NLR <3.0 (HR=9.96, 95% CI=1.28-77.7; p=0.028) were independent factors predictive of durable clinical benefit. In addition, pre-treatment NLR <3.0 (HR=0.34, 95% CI=0.16-0.74; p=0.0059) and male sex (HR=0.23, 95% CI=0.10-0.52; p<0.001) were independent factors predictive of better progression-free survival.
Conclusion: This retrospective study found that baseline NLR predicts the efficacy of eribulin for STS.
(Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
